![]() ![]() ![]() Stephen Vertucci and his team of associates effectively and clearly communicate while maintaining focus on the ‘Big Picture’. If you are faced with urgency to get emergency orders in Colorado or any other family law issue, you will find experienced and deeply committed legal representation at The Law Office of Stephen Vertucci, LLC. Legal Advocacy for Your Colorado Divorce, Separation, Custody, Support, or Other Family Law Matter Having competent, professional legal guidance can make the process less stressful and empower you to move forward with the next phase of your life. In many cases, emotions cloud judgment and stand in the way of resolution and healing. The divorce lawyers at The Law Office of Stephen Vertucci offer consultations to people experiencing a legal separation or divorce.ĭivorce can be one of the most difficult life decisions to make. In these cases, you should seriously consider having an experienced Fort Collins divorce attorney to guide you through this process. ![]() In a marriage of some duration, with children and various types of assets, fair and reasonable division of marital property and determination of child custody, child support, and spousal support can become extremely complex. The Fort Collins family law attorneys at The Law Office of Stephen Vertucci have years of experience handling separation, custody and support issues throughout Colorado. ).Fort Collins Colorado Family Law Attorneys (Funded by Sanofi and Regeneron Pharmaceuticals ODYSSEY OUTCOMES number, NCT01663402. 2.1% in the placebo group).Īmong patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo. The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8% in the alirocumab group vs. The absolute benefit of alirocumab with respect to the composite primary end point was greater among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter than among patients who had a lower baseline level. A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85 95% CI, 0.73 to 0.98). A composite primary end-point event occurred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85 95% confidence interval, 0.78 to 0.93 P<0.001). The median duration of follow-up was 2.8 years. The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non-high-density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose. ![]() We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |